

Press Release – Hannover, Germany & Basel, Switzerland June 27<sup>th</sup> 2006

## Genedata Collaborates with €12.6M European Cancer Research Consortium

Genedata announces its partnership with the Infections and Cancer (INCA) consortium, a European Commission research program to discover the role of chronic infection in the development of cancer. The Swiss-based bioinformatics company will provide research informatics for the consortium's efforts to improve cancer diagnosis and treatment.

An estimated 17% of human cancers are caused by chronic infection. Cancer results from the progressive accumulation of genetic changes to the body's healthy regulation of cell growth. It arises when these changes cause cells to proliferate uncontrollably. The International Agency for Research on Cancer recognizes 9 viral and bacterial agents that appear to provoke this biological chain of events.

"INCA will help researchers develop new prevention measures and treatments against cancers such as leukemia, stomach cancer, and cervical cancer", explained Professor Thomas Schulz, INCA's principal coordinator based at Hannover Medical School, Germany. The consortium will focus on five viruses and one bacterium, the gut-dwelling *Helicobacter pylori*, to investigate how chronic infections and inflammation can interfere with normal cellular functioning.

Techniques like gene expression profiling reveal 100's or even thousands of genes that are apparently active in a particular disease state. Such results require specialized statistical processing. INCA will exploit existing biological knowledge of inflammatory pathways to interpret high throughput data measuring transcriptomic, proteomic and metabolomic activity. Professor Schulz added, "Genedata's informatics resources will help us gain the best advantage from genome-wide experimental investigations".

"We are proud to provide the research informatics infrastructure for this important cancer research program", says Dr. Othmar Pfannes, CEO of Genedata AG. Genedata will integrate high throughput molecular data and provide quantitative data analysis and training services. Dr. Pfannes added, "Our computational solutions are tailored for collaborative settings and provide a valuable informatics foundation for consortia-based research efforts".

---

### Contact

Genedata AG  
Dr. Tobe Freeman  
Manager Public Relations

INCA  
Professor Thomas Schulz

Institut für Virologie  
Medizinische Hochschule Hannover Carl-Neuberg-Str. 1  
30625 Hannover  
Germany

Phone +41 61 697 8510  
Fax +41 61 697 7244  
tobe.freeman@genedata.com  
www.genedata.com

info@inca-project.org  
[www.inca-project.org](http://www.inca-project.org)

**INCA** began operation on January 1st this year and will run for 4 years. It will receive €12.6M of EC funding (Project INCA: LSHC-CT-2005-018704) as part of Europe's Framework 6 Life-Science-Health program and involves 30 research institutes and enterprises hailing from 13 European countries. Further information is available at [www.inca-project.org](http://www.inca-project.org).

**Genedata** specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data. Genedata Screener® for high throughput screening analysis. And Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Japan, Taiwan and Singapore. For more information about Genedata, please visit: [www.genedata.com](http://www.genedata.com).

---

**Disclaimer**

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.